文献速递头颈部肿瘤放疗

达克替尼与gedatolisib联合分次放疗在头颈癌中的研究

Dacomitinib and gedatolisib in combination with fractionated radiation in head and neck cancer.
PubMed 文献 · Clin Transl Radiat Oncol · 2020-11-08

本研究在低传代头颈鳞癌(HNSCC)异种移植模型中,体外和体内评估达克替尼(pan-HER不可逆抑制剂)与gedatolisib(PI3K/MTOR双重抑制剂)联合放疗的效果。结果显示达克替尼单药及联合放疗有效,但加入gedatolisib未增强疗效,两药联合放疗较单药最有效药物无额外获益。

要点

  • 达克替尼体外抑制生长与EGFR表达相关,gedatolisib对两株细胞均有效。
  • 两药体外均未使细胞系发生放射增敏。
  • 体内达克替尼单药及联合放疗有效,加gedatolisib未增强疗效。

核心结论

  • 两药联合放疗较单药最有效药物无额外获益,达克替尼值得作为HNSCC放射增敏剂进一步研究。

研究设计与样本

  • 在特征明确的低传代HNSCC异种移植模型中进行体外和体内研究。

主要发现

  • 达克替尼体外生长抑制呈差异性与EGFR表达相关,gedatolisib对两株细胞系均有效。
  • 两药体外均未放射增敏细胞系。
  • 体内达克替尼单药及联合放疗有效,加gedatolisib未增强两 modalities 效果,尽管抑制了PI3K/MTOR通路关键基因磷酸化。

临床怎么用

  • 达克替尼可作为HNSCC放射增敏候选药物进一步研究,联合PI3K/MTOR抑制剂未显示额外获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: There has been little success targeting individual genes in combination with radiation in head and neck cancer. In this study we investigated whether targeting two key pathways simultaneously might be more effective. MATERIALS AND METHODS: We studied the effect of combining dacomitinib (pan-HER, irreversible inhibitor) and gedatolisib (dual PI3K/MTOR inhibitor) with radiation in well characterized, low passage xenograft models of HNSCC in vitro and in vivo. RESULTS: Dacomitinib showed differential growth inhibition in vitro that correlated to EGFR expression whilst gedatolisib was effective in both cell lines. Neither agent radiosensitized the cell lines in vitro. In vivo studies demonstrated that dacomitinib was an effective agent alone and in combination with radiation whilst the addition of gedatolisib did not enhance the effect of these two modalities despite inhibiting phosphorylation of key genes in the PI3K/MTOR pathway. CONCLUSIONS: Our results showed that combining two drugs with radiation provided no added benefit compared to the single most active drug. Dacomitinib deserves more investigation as a radiation sensitizing agent in HNSCC.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Wilson GD, Wilson TG, Hanna A, et al. Dacomitinib and gedatolisib in combination with fractionated radiation in head and neck cancer. Clin Transl Radiat Oncol. 2020. PMID: 33251343. doi:10.1016/j.ctro.2020.11.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。